Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 629-637

  Chen, Hui Jye ^a   Lin, Chung Ming ^c   Lee, Chao Ying ^a   Shih, Nai Chen ^a   Amagaya, Sakae ^d   Lin, Yung Chang ^b   Yang, Jai Sing ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c MING CHUAN UNIVERSITY   (Taiwan)

^d NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

EGFR; Invasion; MMP 2; MMP 9; OSCC SAS cells; Phenethyl isothiocyanate

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHENETHYL ISOTHIOCYANATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR; HUMANS; I-KAPPA B KINASE; ISOTHIOCYANATES; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84879667745     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1977     Document Type: Article

References (68)

1. Noguti J, De Moura CF, De Jesus GP, et al: Metastasis from oral cancer: an overview. Cancer Genomics Proteomics 9: 329-335, 2012.
2. Sarode SC, Sarode GS, Karmarkar S and Tupkari JV: A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 47: 920-921, 2011.
3. Seethala RR, Gooding WE, Handler PN, et al: Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 14: 1303-1309, 2008. (Pubitemid 351413908)
4. Franceschi S, Bidoli E, Baron AE, et al: Nutrition and cancer of the oral cavity and pharynx in north-east Italy. Int J Cancer 47: 20-25, 1991.
5. Velly AM, Franco EL, Schlecht N, et al: Relationship between dental factors and risk of upper aerodigestive tract cancer. Oral Oncol 34: 284-291, 1998. (Pubitemid 28318255)
6. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM and Tsai CC: Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24: 450-453, 1995.
7. Ichimiya Y, Fuwa N, Kamata M, et al: Treatment results of stage I oral tongue cancer with definitive radiotherapy. Oral Oncol 41: 520-525, 2005. (Pubitemid 40692854)
8. Xi S and Grandis JR: Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 82: 11-16, 2003.
9. Pereira MC, Oliveira DT, Landman G and Kowalski LP: Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc 73: 339-344, 2007.
10. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
11. Okura M, Aikawa T, Sawai NY, Iida S and Kogo M: Decision analysis and treatment threshold in a management for the N0 neck of the oral cavity carcinoma. Oral Oncol 45: 908-911, 2009.
12. Greenberg JS, Fowler R, Gomez J, et al: Extent of extracapsular spread: a critical prognosticator in oral tongue cancer. Cancer 97: 1464-1470, 2003. (Pubitemid 36297776)
13. Stan SD, Kar S, Stoner GD and Singh SV: Bioactive food components and cancer risk reduction. J Cell Biochem 104: 339-356, 2008.
14. Stan SD, Singh SV and Brand RE: Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 7: 347-356, 2010.
15. Keum YS, Jeong WS and Kong AN: Chemopreventive functions of isothiocyanates. Drug News Perspect 18: 445-451, 2005.
16. Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y and Shields PG: Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 134: 1134-1138, 2004. (Pubitemid 38619952)
17. Greenwald P, Clifford CK and Milner JA: Diet and cancer prevention. Eur J Cancer 37: 948-965, 2001. (Pubitemid 32401123)
18. Conaway CC, Yang YM and Chung FL: Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 3: 233-255, 2002. (Pubitemid 34625038)
19. Hecht SS: Inhibition of carcinogenesis by isothiocyanates. Drug Metab Rev 32: 395-411, 2000.
20. Fahey JW, Zalcmann AT and Talalay P: The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 56: 5-51, 2001. (Pubitemid 32063165)
21. Hayes JD, Kelleher MO and Eggleston IM: The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr 47 (Suppl 2): 73-88, 2008. (Pubitemid 351644183)
22. Kumar A and Sabbioni G: New biomarkers for monitoring the levels of isothiocyanates in humans. Chem Res Toxicol 23: 756-765, 2010.
23. Khor TO, Cheung WK, Prawan A, Reddy BS and Kong AN: Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 47: 321-325, 2008. (Pubitemid 351614572)
24. Moy KA, Yuan JM, Chung FL, et al: Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17: 1354 -1359, 2008.
25. Hecht SS: Chemoprevention by isothiocyanates. J Cell Biochem (Suppl 22): 195-209, 1995.
26. Zhang Y: Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res 555: 173-190, 2004.
27. Xiao D, Johnson CS, Trump DL and Singh SV: Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 3: 567-575, 2004. (Pubitemid 39193735)
28. Huong le D, Shim JH, Choi KH, et al: Effect of beta-phenylethyl isothiocyanate from cruciferous vegetables on growth inhibition and apoptosis of cervical cancer cells through the induction of death receptors 4 and 5. J Agric Food Chem 59: 8124-8131, 2011.
29. Yan H, Zhu Y, Liu B, et al: Mitogen-activated protein kinase mediates the apoptosis of highly metastatic human non-small cell lung cancer cells induced by isothiocyanates. Br J Nutr 106: 1779-1791, 2011.
30. Chen YR, Han J, Kori R, Kong AN and Tan TH: Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem 277: 39334-39342, 2002. (Pubitemid 35190906)
31. Hwang ES and Lee HJ: Effects of phenylethyl isothiocyanate and its metabolite on cell-cycle arrest and apoptosis in LNCaP human prostate cancer cells. Int J Food Sci Nutr 61: 324-336, 2010.
32. Xu C, Shen G, Chen C, Gelinas C and Kong AN: Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24: 4486-4495, 2005. (Pubitemid 41032612)
33. Bommareddy A, Hahm ER, Xiao D, et al : Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 69: 3704-3712, 2009.
34. Wu X, Kassie F and Mersch-Sundermann V: Induction of apoptosis in tumor cells by naturally occurring sulfur-containing compounds. Mutat Res 589: 81-102, 2005. (Pubitemid 40431689)
35. Morse MA, Amin SG, Hecht SS and Chung FL: Effects of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res 49: 2894-2897, 1989. (Pubitemid 19148621)
36. Zhang Y, Kensler TW, Cho CG, Posner GH and Talalay P: Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150, 1994. (Pubitemid 24130192)
37. Powolny AA, Bommareddy A, Hahm ER, et al : Chemo-preventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst 103: 571-584, 2011.
38. Kelloff GJ, Crowell JA, Hawk ET, et al: Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem (Suppl 26): 54-71, 1996. (Pubitemid 27203752)
39. Yang MD, Lai KC, Lai TY, et al: Phenethyl isothiocyanate inhibits migration and invasion of human gastric cancer AGS cells through suppressing MAPK and NF-kappaB signal pathways. Anticancer Res 30: 2135-2143, 2010.
40. Lai KC, Huang AC, Hsu SC, et al: Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 58: 2935-2942, 2010.
41. Xiao D and Singh SV: Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 67: 2239-2246, 2007. (Pubitemid 46424243)
42. Lu KW, Chen JC, Lai TY, et al: Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum Exp Toxicol 30: 406-415, 2011.
43. Hour MJ, Tsai SC, Wu HC, et al: Antitumor effects of the novel quinazolinone MJ-33: Inhibition of metastasis through the MAPK, AKT, NF-kappaB and AP-1 signaling pathways in DU145 human prostate cancer cells. Int J Oncol 41: 1513-1519, 2012.
44. Ohnishi Y, Lieger O, Attygalla M, Iizuka T and Kakudo K: Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. Oral Oncol 44: 1155-1159, 2008.
45. Yang JS, Liu CW, Ma YS, et al: Chlorogenic acid induces apoptotic cell death in U937 leukemia cells through caspase- and mitochondria-dependent pathways. In Vivo 26: 971-978, 2012.
46. Lan YH, Chiang JH, Huang WW, et al: Activations of both extrinsic and intrinsic pathways in HCT 116 human colorectal cancer cells contribute to apoptosis through p53-mediated ATM/Fas signaling by Emilia sonchifolia extract, a folklore medicinal plant. Evid Based Complement Alternat Med 2012: 178178, 2012.
47. Tsai SC, Huang WW, Huang WC, et al: ERK-modulated intrinsic signaling and G(2)/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells. Int J Oncol 41: 2065-2072, 2012.
48. Kao WT, Lin CY, Lee LT, et al: Investigation of MMP-2 and -9 in a highly invasive A431 tumor cell sub-line selected from a Boyden chamber assay. Anticancer Res 28: 2109-2120, 2008.
49. Chen KT, Hour MJ, Tsai SC, et al: The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor. Int J Oncol 39: 611-619, 2011.
50. Yang JS, Wu CC, Kuo CL, et al: Solanum lyratum extracts induce extrinsic and intrinsic pathways of apoptosis in WEHI-3 murine leukemia cells and inhibit allograft tumor. Evid Based Complement Alternat Med 2012: 254960, 2012.
51. Chiu YJ, Hour MJ, Lu CC, et al: Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway. J Orthop Res 29: 1448-1456, 2011.
52. Bjorklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755: 37-69, 2005. (Pubitemid 40720240)
53. Bode W, Fernandez-Catalan C, Grams F, et al: Insights into MMP-TIMP interactions. Ann NY Acad Sci 878: 73-91, 1999. (Pubitemid 29353561)
54. Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672, 2006. (Pubitemid 46622088)
55. Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 1: 11, 2006.
56. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P and Eccles SA: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24: 47-69, 2005. (Pubitemid 40576063)
57. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003. (Pubitemid 36163619)
58. Lo HW and Hung MC: Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94: 184-188, 2006.
59. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (Suppl 4): S3-S8, 2001.
60. Temam S, Kawaguchi H, El-Naggar AK, et al: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25: 2164-2170, 2007. (Pubitemid 46954638)
61. Chung CH, Ely K, McGavran L, et al: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176, 2006. (Pubitemid 46622295)
62. Kim JH, Xu C, Keum YS, Reddy B, Conney A and Kong AN: Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27: 475-482, 2006. (Pubitemid 43372876)
63. Thomas GT, Lewis MP and Speight PM: Matrix metalloproteinases and oral cancer. Oral Oncol 35: 227-233, 1999. (Pubitemid 29148354)
64. Xiao D, Choi S, Lee YJ and Singh SV: Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Mol Carcinog 43: 130-140, 2005. (Pubitemid 40944238)
65. Huong LD, Shin JA, Choi ES, et al: beta-Phenethyl isothiocyanate induces death receptor 5 to induce apoptosis in human oral cancer cells via p38. Oral Dis 18: 513-519, 2012.
66. Yang YM, Conaway CC, Chiao JW, et al: Inhibition of benzo(a)pyrene- induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res 62: 2-7, 2002. (Pubitemid 34073975)
67. Xiao D and Singh SV: Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 62: 3615-3619, 2002. (Pubitemid 34728834)
68. Hu R, Kim BR, Chen C, Hebbar V and Kong AN: The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells. Carcinogenesis 24: 1361-1367, 2003. (Pubitemid 37038826)